Does Peppermint Oil IBS Randomized Trial work?

Updated August 2026

Quick Answer

Peppermint Oil IBS Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: Young adults, particularly females, have a higher prevalence, which has increased substantially over the past decades [].

Key Takeaways

  • 01Young adults, particularly females, have a higher prevalence, which has increased substantially over the past decades []. [Pastras Ploutarchos (2026)]
  • 02More specifically, the presence of recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, associated with two or more of the following: symptoms related to defecation, a change in stool frequency, or a change in stool form []. [Pastras Ploutarchos (2026)]
  • 03IBS is associated with reduced engagement in daily activities, increased work absenteeism, and impaired functioning, thereby increasing the global healthcare burden []. [Pastras Ploutarchos (2026)]
  • 041 2 1 3 1 4 5 Disorders of gut–brain interaction (DGBIs) are functional gastrointestinal conditions characterized by a complex interplay between the gut and the brain []. [Pastras Ploutarchos (2026)]
The current Migaku evidence database contains 2 reusable source documents for Peppermint Oil IBS Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove. - Young adults, particularly females, have a higher prevalence, which has increased substantially over the past decades []. [Pastras Ploutarchos (2026); evidence level 2] - More specifically, the presence of recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, associated with two or more of the following: symptoms related to defecation, a change in stool frequency, or a change in stool form []. [Pastras Ploutarchos (2026); evidence level 2] - IBS is associated with reduced engagement in daily activities, increased work absenteeism, and impaired functioning, thereby increasing the global healthcare burden []. [Pastras Ploutarchos (2026); evidence level 2] - 1 2 1 3 1 4 5 Disorders of gut–brain interaction (DGBIs) are functional gastrointestinal conditions characterized by a complex interplay between the gut and the brain []. [Pastras Ploutarchos (2026); evidence level 2] - 1 2 3 4 5 5 6 7 6 7 Irritable bowel syndrome (IBS) is a chronic disorder of gut–brain interaction characterized by recurrent abdominal pain associated with altered bowel habits, in the absence of identifiable structural abnormalities []. [Šuran Jelena (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines
  2. IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions